Evaluation of the Benefits of a Newly Marketed Vaginal Gel (Palomacare®) on Vaginal Health of Peri and Postmenopausal Women (Atrovag Survey)

Santiago Palacios¹, Fernando Losa², Josep Combalia³, Carine Emsellem¹, Yann Gaslain³ and Danial Khorsandi¹,²,³*,⁴,⁵

¹Palacios Institute of Women’s Health and Medicine, Madrid, Spain
²Sagrada Familia Clinic, Barcelona, Spain
³Procare Health Iberia, Castelldefels, Barcelona, Spain
⁴University of Barcelona, Barcelona, Spain
⁵Harvard-MIT’s Division of Health Science and Technology, MA, USA

*Corresponding Author: Danial Khorsandi, Department of Molecular Biotechnology, University of Barcelona, Harvard-MIT’s Division of Health Science and Technology, Procare Health Iberia, Spain.

Citation: Danial Khorsandi., et al. “Evaluation of the Benefits of a Newly Marketed Vaginal Gel (Palomacare®) on Vaginal Health of Peri and Postmenopausal Women (Atrovag Survey)”.

Abstract

Objective: To determine the opinion of doctors in relation to the overall satisfaction of patients with the use of Palomacare®, a multi-ingredient, non-hormonal vaginal gel with moisturizing and restorative properties indicated for the improvement of symptoms and signs that make up the genitourinary syndrome, after its recent commercialization.

Methods: The atrovag survey was addressed during the first quarter of 2017 to Spanish Gynaecologists who were visiting women that already were using Palomacare®. At the end, collected data were analyzed.

Results: A total of 143 doctors participated in the survey. 84% of the respondents indicated an improvement of vaginal dryness in more than 60% of their patients. An improvement in quality and no or less pain in sexual relations was pointed out by 80% of doctors. Vaginal elasticity, moisture, and epithelial integrity were vaginal health parameters with a significant improvement according to 38%, 24% and 17% of participants, respectively.

Conclusion: After analyzing the data we assured that Palomacare® is a product with a good effectiveness and tolerance perception that make it highly satisfactory by prescribers and considered better than other previous treatments by their users.

Keywords: Palomacare®, Vaginal Health, Atrovag Survey

Introduction

There are several symptoms that cause discomfort in women due to vaginal atrophy such as Dryness, Itching, and Pain during sex and increased risk of genitourinary infections.

This is due to the insufficient amount of estrogen, as happens in physiological situations such as Menopause, Postpartum, Pregnancy, and Lactation.

There are also other situations that cause a deficit of estrogen, such as surgery with removal of ovaries, chemo or radiotherapy, intense physical exercise, smoking, stress and depressive states. Finally, hormonal contraceptives, broad-spectrum antibiotics and hypersensitivity to chemical substances (aggressive soaps, intimate deodorants, synthetic fiber underwear, etc.) can also impair vaginal health.

In any product administered vaginally, periodic evaluation of the advantages, disadvantages, effects, and benefits perceived by prescribers and users can help to improve the habits and conditions of its prescription and use, and as consequence, the adherence and the effectiveness. Even more when the product has a novel formulation and it has relatively little time available in pharmacies.

Palomacare® is a vaginal gel prepared by an innovative formula, based on natural ingredients, developed through Niosomal and Phytosomal biotechnology, which facilitates the penetration of the active ingredients in the vaginal epithelium marketed in Spain since July 2015 that is applied as a vaginal gel. It has moisturizing and restorative properties of the vaginal mucosa and is indicated for the improvement of symptoms and signs that make up the genitourinary syndrome [1-10].

Objective of the Study

The objective of this survey was to know the perception of the Palomacare® effectiveness that have both the prescribing physicians and pre and postmenopausal women after almost two years of commercialization.

Methods

The Atrovag survey was addressed during the first quarter of 2017 to Spanish gynecologists who were visiting women who already were using Palomacare® (10 questions) and to women using Palomacare® (five questions). Most out of 418 participant women were using Palomacare® between 2 and 6 months. During the study, all the gynecologists who were involved have been checking the patients and the improvement of them. A double entry of information in Excel file was performed to assure the quality of the data.

Results

A total of 143 doctors participated in the survey, 99% of whom with 5 or more patients using Palomacare®. Main product benefits stand out by participants are shown in figure 1.

![Main Benefits of Palomacare®](image1)

**Figure 1:** What benefit do women especially stand out in relation with the use of Palomacare®?

84% of the survey respondents indicated an improvement of vaginal dryness in more than 60% of their patients. An improvement in quality and no or less pain in sexual relations was point out by 80% of doctors.

Vaginal elasticity, moisture, and epithelial integrity were vaginal health parameters with a significant improvement according to 38%, 24% and 17% of participants, respectively. Overall, 86% of the doctors said that no patient had reported any adverse effect.

Stinging/burning was the most adverse effect indicated by the participants (6%) followed by itching/Irritation and sensation of product lost (4% each).

Discussion

Most out of 418 participant women were using Palomacare® between 2 and 6 months. Main results of survey addressed to users are shown in figure 2. As a conclusion, Palomacare® is a product with a good effectiveness and tolerance perception that make it highly satisfactory by prescribers and considered better than other previous treatments by their users.

![Women survey data](image2)

**Figure 2:** Results of women survey

There is no any similar product in the market to compare Palomacare® results with their results. In addition, more extensive research must be done to evaluate its potential use for prevention and/or treatment of genital tract infections and confirm these exciting results.

Bibliography


**Volume 7 Issue 3 March 2018**
© All rights reserved by Danial Khorsandi, et al.